Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans and has the potential to progress locally, metastasize, and cause death in a subset of patients. cSCC is especially common in the elderly, and it will probably represent a major health concern in the near future. Surgery is the standard treatment for cSCC, but intralesional therapies can sometimes be considered for certain patients and under certain circumstances. The choice of intralesional treatment depends on the patient′s characteristics and the clinician′s previous experience and expertise. Here we are reviewing intralesional treatments for cSCC and keratoacanthoma (KA). We have started with some classic drugs, such as methotrexate and 5-fluorouracil, bleomycin, interferon, and cryosurgery, but also comment on electrochemotherapy. Finally, we have focused on novel therapies, some of which are under development, and future perspectives, including intralesional immunotherapy and oncolytic viruses.
皮肤鳞状细胞癌（cSCC）是人类第二常见的恶性肿瘤，部分患者可能出现局部进展、转移甚至死亡。该疾病在老年群体中尤为高发，预计在不久的将来将成为重要的公共卫生问题。手术是cSCC的标准治疗方案，但在特定情况下可考虑对部分患者采用病灶内治疗。病灶内治疗方案的选择需综合考虑患者个体特征及临床医生的既往经验与专业判断。本文系统综述了cSCC与角化棘皮瘤（KA）的病灶内治疗方法，涵盖甲氨蝶呤、5-氟尿嘧啶、博来霉素、干扰素及冷冻手术等经典药物与疗法，并对电化学疗法进行评述。最后重点探讨了包括病灶内免疫疗法和溶瘤病毒在内的新型治疗策略（部分尚处于研发阶段）及其未来发展方向。
Intralesional Treatments for Invasive Cutaneous Squamous Cell Carcinoma
肿瘤(癌症)患者之家